Literature DB >> 16556844

Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration.

Anita S Chong1, Jikun Shen, Jing Tao, Dengping Yin, Andrey Kuznetsov, Manami Hara, Louis H Philipson.   

Abstract

Autoimmune destruction of beta cells is the predominant cause of type 1 diabetes mellitus (T1DM) in humans and is modeled in non-obese diabetic (NOD) mice. Many therapeutic interventions prevent the development of T1DM in NOD mice, but few can induce its reversal once established. Intervention with Freund's complete adjuvant, semi-allogeneic splenocytes, and temporary islet transplantation has been reported to cure NOD mice of established T1DM. Using the same approach, we report here that this treatment cured 32% of NOD mice of established diabetes (>340 milligrams per deciliter blood glucose), although beta cells in these mice were not derived from donor splenocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556844     DOI: 10.1126/science.1123510

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  37 in total

1.  Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation.

Authors:  Meritxell Rovira; Wei Huang; Shamila Yusuff; Joong Sup Shim; Anthony A Ferrante; Jun O Liu; Michael J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

2.  Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.

Authors:  Richard A O'Connor; Xujian Li; Seth Blumerman; Stephen M Anderton; Randolph J Noelle; Dyana K Dalton
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

3.  Targeted ablation of beta cells in the embryonic zebrafish pancreas using E. coli nitroreductase.

Authors:  Harshan Pisharath; Jerry M Rhee; Michelle A Swanson; Steven D Leach; Michael J Parsons
Journal:  Mech Dev       Date:  2006-12-08       Impact factor: 1.882

Review 4.  Cellular therapies for type 1 diabetes.

Authors:  D D Lee; E Grossman; A S Chong
Journal:  Horm Metab Res       Date:  2008-02       Impact factor: 2.936

Review 5.  Liver-spleen axis: intersection between immunity, infections and metabolism.

Authors:  Giovanni Tarantino; Antonella Scalera; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

6.  Anti-diabetic effect of a novel oligosaccharide isolated from Rosa canina via modulation of DNA methylation in Streptozotocin-diabetic rats.

Authors:  Gholamreza Bahrami; Soraya Sajadimajd; Bahareh Mohammadi; Razieh Hatami; Shahram Miraghaee; Samira Keshavarzi; Mozafar Khazaei; Seyed Hamid Madani
Journal:  Daru       Date:  2020-08-03       Impact factor: 3.117

7.  Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.

Authors:  Francesca Fallarino; Giovanni Luca; Mario Calvitti; Francesca Mancuso; Claudio Nastruzzi; Maria C Fioretti; Ursula Grohmann; Ennio Becchetti; Anne Burgevin; Roland Kratzer; Peter van Endert; Louis Boon; Paolo Puccetti; Riccardo Calafiore
Journal:  J Exp Med       Date:  2009-10-12       Impact factor: 14.307

8.  Cdk4 regulates recruitment of quiescent beta-cells and ductal epithelial progenitors to reconstitute beta-cell mass.

Authors:  Ji-Hyeon Lee; Junghyo Jo; Anandwardhan A Hardikar; Vipul Periwal; Sushil G Rane
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

Review 9.  Slow and steady is the key to beta-cell replication.

Authors:  Kristen Brennand; Doug Melton
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

10.  Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice.

Authors:  Eric J Grossman; David D Lee; Jing Tao; Raphael A Wilson; Soo-Young Park; Graeme I Bell; Anita S Chong
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.